Semantic Scholar uses AI to extract papers important to this topic.
Abstract4-1BB (CD137, TNFRSF9) is an inducible costimulatory receptor expressed on activated T cells. Clinical trials of two… Expand e14626Background: Urelumab (BMS-663513) is a humanized monoclonal antibody binding to CD137 which, upon Fc-clustering, leads to… Expand In the past 5 years, immunomodulatory antibodies have revolutionized cancer immunotherapy. CD137, a member of the tumor necrosis… Expand 3017 Background: Anti-CD137 antibody was shown in both murine cancer models and in a first-in-human, phase I trial (Sznol et al… Expand TPS3108 Background: CD137 (4-1BB) is a costimulatory molecule that belongs to the TNF superfamily. It is upregulated on activated… Expand Knowledge of how the immune system recognizes and attempts to control cancer growth and development has improved dramatically… Expand 3007 Background: CD137 is a member of the TNFR family and functions as a costimulatory molecule. In preclinical studies BMS… Expand Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand